Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Enhancing Lung Cancer Therapy with Nutrient Supplementation

EF 2019-20

Résumé
"Over 29,000 Canadians will receive a devastating diagnosis of lung cancer in 2019; the majority with non-small cell lung cancer (NSCLC). Most often diagnosed at an incurable stage, NSCLC is treated with chemotherapy and immunotherapy to slow tumor growth and extend survival. This disease and it's treatments, however, can have difficult side effects including muscle wasting and profound weight loss, negatively affecting quality of life, functional ability, and the ability to tolerate the recommended treatment. This rapid weight loss is known as cancer-associated weight loss, and cannot be prevented or reversed simply by increasing food intake. Often patients express the feeling of 'living in someone else's body' because of the profound physical and functional changes associated with NSCLC and it's treatment. To support optimal quality of life, strength and function, new strategies to prevent or reduce muscle wasting and weight loss are urgently needed. Results from early phase studies suggest that a novel nutrient supplement taken during treatment may slow or stop muscle loss associated with advanced NSCLC. This same nutrient has been shown to enhance the benefit of chemotherapy, resulting in improved tumor response (reduced size or stable disease). However, this nutrient has not been tested with immunotherapy, which is a recent addition to the standard-of-care. Large, well-designed studies are required to confirm previous results and provide evidence for the use of this nutrient supplement in current clinical practice with immunotherapy. My research study aims to evaluate whether supplementation with this novel nutrient can improve the benefit of standard treatment for NSCLC while preserving muscle, physical function and quality of life for patients. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428905
Name
Klassen Pamela
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Lung Cancer Therapy with Nutrient Supplementation
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Disease Control Rate; Docosahexaenoic Acid; Eicosapentaenoic Acid; Fatty Acid; Immunotherapy; Myosteatosis; Omega-3; Skeletal Muscle Mass
Abstract
"Over 29,000 Canadians will receive a devastating diagnosis of lung cancer in 2019; the majority with non-small cell lung cancer (NSCLC). Most often diagnosed at an incurable stage, NSCLC is treated with chemotherapy and immunotherapy to slow tumor growth and extend survival. This disease and it's treatments, however, can have difficult side effects including muscle wasting and profound weight loss, negatively affecting quality of life, functional ability, and the ability to tolerate the recommended treatment. This rapid weight loss is known as cancer-associated weight loss, and cannot be prevented or reversed simply by increasing food intake. Often patients express the feeling of 'living in someone else's body' because of the profound physical and functional changes associated with NSCLC and it's treatment. To support optimal quality of life, strength and function, new strategies to prevent or reduce muscle wasting and weight loss are urgently needed. Results from early phase studies suggest that a novel nutrient supplement taken during treatment may slow or stop muscle loss associated with advanced NSCLC. This same nutrient has been shown to enhance the benefit of chemotherapy, resulting in improved tumor response (reduced size or stable disease). However, this nutrient has not been tested with immunotherapy, which is a recent addition to the standard-of-care. Large, well-designed studies are required to confirm previous results and provide evidence for the use of this nutrient supplement in current clinical practice with immunotherapy. My research study aims to evaluate whether supplementation with this novel nutrient can improve the benefit of standard treatment for NSCLC while preserving muscle, physical function and quality of life for patients. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Klassen, Pamela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~